



दूरभाष स./Tel. No.:011-22393703; ई-मेल/E-mail: dirdcd@nic.in; वेबसाइट/website:https://drugs.delhi.gov.in

F. No. 13(15)/Misc./HQ/2017/4429-4432

Dated: 17/09/25

**CIRCULAR**

This is with reference to the recommendations of the 56<sup>th</sup> GST council meeting held on 03.09.2025 regarding rationalization of Goods & Services Tax (GST) rate structures, wherein the GST rates of drugs/formulations & other medical products including medical devices have been reduced and same will be effective from 22.09.2025.

In this connection, this Department is issuing following instructions for necessary compliance by concerned stakeholders located in jurisdiction of Govt. of NCT of Delhi:

- All the manufacturers and marketer of drugs, formulations & medical devices located in the jurisdiction of Delhi are required to revise the Maximum Retail Price (MRP) of drugs, formulations and medical devices as per revised GST rate w.e.f. 22.09.2025.
- All the manufacturers of drugs & formulations may alter the label through stamping / stickering / printing the products limited to only revision of MRP to the extent of revised GST rate without affecting other part of label of such products (including original MRP) after obtaining necessary No Objection Certificate from State Licensing Authority under Rule 104A of Drugs Rules, 1945.
- In exercise of the powers conferred under Rule 8 of Medical Devices Rules, 2017, State Licensing Authority has no objection to alteration of label through stamping / stickering / printing by the manufacturers of Class A and Class B medical devices, limited to only revision of MRP to the extent of revised GST rate without affecting other part of label of such products (including original MRP).
- The above alteration of labels of products to be done in phased manner so as to not cause shortage of the product in the market.
- All the manufacturers of drugs, formulations & medical devices are required to take all the necessary steps to ensure that concerned stakeholder in supply chain up to retailer level comply with the revised MRP with effect from 22.09.2025.

  
17/09/25

- f) All the manufacturers of drugs, formulations & medical devices are required to issue the revised price list to retailer & other dealers in supply chain under intimation to this Department.
- g) All the retailers and wholesalers are also directed to update their billing including the online software used for billing purpose with the revised GST rate with effect from 22.09.2025.

This is for information of all stakeholders for their information and necessary compliance.




(K. R. Chawla)  
Head of Office /  
Controlling Authority

F. No. 13(15)/Misc./HQ/2017/4429 - 4432

Dated: 17/09/25

**Copy to:**

- a) Drugs Controller, Drugs Control Department, GNCTD
- b) The President, Manufacturer Association of Delhi
- c) The President, Chemist Associations of Delhi
- d) Guard File



(K. R. Chawla)  
Head of Office /  
Controlling Authority